CTI BioPharma (CTIC) Stock Price, News & Analysis

Company Overview

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.

Key Stats

• Today's Range: $9.09 to $9.09
• 50-Day Range: $8.91 to $9.10
• 52-Week Range: $4.01 to $9.10
• Volume: N/A
• Average Volume: 4.50 million shs
• Market Capitalization: $1.20 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CTIC Stock Analysis - Frequently Asked Questions

How were CTI BioPharma's earnings last quarter?

CTI BioPharma Corp. (NASDAQ:CTIC) announced its quarterly earnings results on Monday, March, 6th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.04. The biopharmaceutical company earned $21.08 million during the quarter, compared to analyst estimates of $24.88 million.

When did CTI BioPharma's stock split?

CTI BioPharma's stock reverse split on Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 30th 2016. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of CTI BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CTI BioPharma investors own include Edap Tms (EDAP), Energous (WATT), Adverum Biotechnologies (ADVM), Weatherford International (WFT), XOMA (XOMA), Advanced Micro Devices (AMD) and Sorrento Therapeutics (SRNE).

Company Calendar

• Last Earnings: 3/06/2023
• Today: 2/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CTIC
• Previous Symbol: NASDAQ:CTICD
• CUSIP: N/A
• CIK: 891293
• Web: www.ctibiopharma.com
• Phone: (206) 282-7100
• Fax: 206-284-6206
• Employees: 127
• Year Founded: 1992

Profitability

• EPS (Most Recent Fiscal Year): ($0.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-92,990,000.00
• Net Margins: -91.38%
• Pretax Margin: -91.38%
• Return on Equity: N/A
• Return on Assets: -55.82%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.27
• Quick Ratio: 1.26

Sales & Book Value

• Annual Sales: $53 million
• Price / Sales: 22.62
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.14) per share
• Price / Book: -64.93

Miscellaneous

• Outstanding Shares: 131,880,000
• Free Float: 121,844,000
• Market Cap: $1.20 billion
• Optionable: Optionable
• Beta: 0.83